A recent review undertook an extensive analysis of AD biomarkers and concluded that thymus- and activation-regulated chemokine/C-C motif ligand 17 (TARC/CCL17) appears to be the most likely candidate for use as a reference biomarker, correlating with the disease severity in all patients, regardless of age [16]. This evidence concerns the gene CCL17 and Alzheimer disease.